Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377136 | 0.87 | TTR (1.00) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5380998 | 0.87 | TTR (1.00) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL14408187 | 0.84 | TTR (0.59) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5380992 | 0.82 | TTR (0.71) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5373126 | 0.79 | TTR (0.67) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5371499 | 0.78 | TTR (0.55) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5376518 | 0.78 | TTR (0.69) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL11235859 | 0.78 | ACMSD (0.75) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5371407 | 0.77 | TTR (0.60) | TTRKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL5371402 | 0.77 | TTR (0.60) | TTRKDM4EMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265245-B2 | Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils | INNOVAPROTEAN, S.L (ES) | 2007-09-04 | — | — | US | claimed |
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | INNOVAPROTEAN, S.L. (ES) | 2007-07-19 | — | — | US | claimed |
| EP-1679299-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | Innovaprotean, S.L. (ES) | 2006-07-12 | — | — | EP | claimed |
| US-7265245-B2 | Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils | INNOVAPROTEAN, S.L (ES) | 2007-09-04 | — | — | US | disclosed |
| US-7265245-B2 | Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils | INNOVAPROTEAN, S.L (ES) | 2007-09-04 | — | — | US | disclosed |
| US-7265245-B2 | Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils | INNOVAPROTEAN, S.L (ES) | 2007-09-04 | — | — | US | disclosed |
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | INNOVAPROTEAN, S.L. (ES) | 2007-07-19 | — | — | US | disclosed |
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | INNOVAPROTEAN, S.L. (ES) | 2007-07-19 | — | — | US | disclosed |
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | INNOVAPROTEAN, S.L. (ES) | 2007-07-19 | — | — | US | disclosed |
| EP-1679299-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | Innovaprotean, S.L. (ES) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167378-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS | APP, C1R, RTN3 | TTR 12/4885KDM4E 4639/4885MEN1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.